300 related articles for article (PubMed ID: 24737128)
1. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
Fackler MJ; Lopez Bujanda Z; Umbricht C; Teo WW; Cho S; Zhang Z; Visvanathan K; Jeter S; Argani P; Wang C; Lyman JP; de Brot M; Ingle JN; Boughey J; McGuire K; King TA; Carey LA; Cope L; Wolff AC; Sukumar S
Cancer Res; 2014 Apr; 74(8):2160-70. PubMed ID: 24737128
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
4. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
Connolly RM; Fackler MJ; Zhang Z; Zhou XC; Goetz MP; Boughey JC; Walsh B; Carpenter JT; Storniolo AM; Watkins SP; Gabrielson EW; Stearns V; Sukumar S
Breast Cancer Res Treat; 2018 Jan; 167(1):107-116. PubMed ID: 28918548
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
Dawson SJ; Tsui DW; Murtaza M; Biggs H; Rueda OM; Chin SF; Dunning MJ; Gale D; Forshew T; Mahler-Araujo B; Rajan S; Humphray S; Becq J; Halsall D; Wallis M; Bentley D; Caldas C; Rosenfeld N
N Engl J Med; 2013 Mar; 368(13):1199-209. PubMed ID: 23484797
[TBL] [Abstract][Full Text] [Related]
8. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.
Matsui S; Kagara N; Mishima C; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Oct; 36(4):2225-35. PubMed ID: 27499429
[TBL] [Abstract][Full Text] [Related]
9. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
[TBL] [Abstract][Full Text] [Related]
11. High performance methylated DNA markers for detection of colon adenocarcinoma.
Klein Kranenbarg RAM; Vali AH; IJzermans JNM; Pisanic TR; Wang TH; Azad N; Sukumar S; Fackler MJ
Clin Epigenetics; 2021 Dec; 13(1):218. PubMed ID: 34903270
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer.
Lin RK; Su CM; Lin SY; Thi Anh Thu L; Liew PL; Chen JY; Tzeng HE; Liu YR; Chang TH; Lee CY; Hung CS
Mol Med; 2022 Jun; 28(1):67. PubMed ID: 35715741
[TBL] [Abstract][Full Text] [Related]
13. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA.
Korshunova Y; Maloney RK; Lakey N; Citek RW; Bacher B; Budiman A; Ordway JM; McCombie WR; Leon J; Jeddeloh JA; McPherson JD
Genome Res; 2008 Jan; 18(1):19-29. PubMed ID: 18032725
[TBL] [Abstract][Full Text] [Related]
14. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Cho YH; Yazici H; Wu HC; Terry MB; Gonzalez K; Qu M; Dalay N; Santella RM
Anticancer Res; 2010 Jul; 30(7):2489-96. PubMed ID: 20682973
[TBL] [Abstract][Full Text] [Related]
16. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.
Matuschek C; Bölke E; Lammering G; Gerber PA; Peiper M; Budach W; Taskin H; Prisack HB; Schieren G; Orth K; Bojar H
Eur J Med Res; 2010; 15(7):277-86. PubMed ID: 20696638
[TBL] [Abstract][Full Text] [Related]
17. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Sturgeon SR; Balasubramanian R; Schairer C; Muss HB; Ziegler RG; Arcaro KF
Epigenetics; 2012 Nov; 7(11):1258-67. PubMed ID: 22986510
[TBL] [Abstract][Full Text] [Related]
18. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
19. Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer.
Fackler MJ; Tulac S; Venkatesan N; Aslam AJ; de Guzman TN; Mercado-Rodriguez C; Cope LM; Downs BM; Vali AH; Ding W; Lehman J; Denbow R; Reynolds J; Buckley ME; Visvanathan K; Umbricht CB; Wolff AC; Stearns V; Bates M; Lai EW; Sukumar S
Cancer Res Commun; 2022 Jun; 2(6):391-401. PubMed ID: 36046124
[TBL] [Abstract][Full Text] [Related]
20. Monitor tumor burden with circulating tumor DNA.
Figg WD; Reid J
Cancer Biol Ther; 2013 Aug; 14(8):697-8. PubMed ID: 23792566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
